Company Overview and News


Add QGEN
to your dashboard

Headline News

Qiagen NV (QGEN) a Hold on Anemic Industry Group Rank

2017-12-07 investorplace
Qiagen NV (NASDAQ:QGEN) is ranked as a Hold using the stock evaluator from Portfolio Grader, which incorporates Louis Navellier's investing methodology. The current Portfolio Grader recommendation on the shares has been in place for the last month. (2-0)

Qiagen NV (QGEN) Sales Growth Restrict Rating

2017-11-30 investorplace
Currently, Qiagen NV (NASDAQ:QGEN) has a Hold using the Portfolio Grader stock evaluator of Louis Navellier, which incorporates his investing system. QGEN has recently seen its Portfolio Grader rating downgraded over the last month from a Buy to a Hold. (2-0)

Brexit Bulletin: Final Offer? - Bloomberg

2017-11-27 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (2-0)

Vapid Quant Score Hurt Qiagen NV (QGEN) Rating

2017-11-23 investorplace
Currently, Qiagen NV (NASDAQ:QGEN) has a Hold using the Portfolio Grader stock evaluator of Louis Navellier, which incorporates his investing methodology. QGEN has recently seen its Portfolio Grader rating downgraded over the last month from a Buy to a Hold. (2-0)

Qiagen N.V. 2017 Q3 - Results - Earnings Call Slides

2017-11-20 seekingalpha
The following slide deck was published by Qiagen N.V. in conjunction with their 2017 Q3 earnings call. (2-0)

Weak Earnings Growth Drops Qiagen NV (QGEN) to Hold

2017-11-16 investorplace
With a $7.2 billion market value, Qiagen NV (NASDAQ:QGEN) ranks in the top half of its industry group, Life Sciences Tools & Services, and in the top 25% of its sector group, Health Care, in market value. From the prospective of investment attractiveness, The current Portfolio Grader ranking for QGEN puts it 23 among the 33 companies in this industry group, giving it a below-average spot; in the third quartile of the sector with a ranking of 453 among the 782 companies in the sector, and number 2,909 in the nearly 5,000 company Portfolio Grader universe. (2-0)

Corporate News Blog - Myriad Teams Up with Department of Veterans Affairs for Clinical Trials to Evaluate the Effectiveness of GeneSight(R) Test in Improving MDD In Veterans

2017-11-13 accesswire
LONDON, UK / ACCESSWIRE / November 13, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Myriad Genetics, Inc. (NASDAQ: MYGN), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=MYGN. The Company's wholly-owned subsidiary, Assurex Health, announced on November 10, 2017, that it has teamed up with the Department of Veterans Affairs (VA) and launched a nationwide, multi-center clinical trial to evaluate the effectiveness of its GeneSight® test. (19-0)

QIAGEN (QGEN) Faces Declining HPV Sales, Intense Competition

2017-11-10 zacks
On Nov 9, we issued an updated research report on QIAGEN N.V. (QGEN - Free Report) . The stock currently carries a Zacks Rank #4 (Sell). (10-0)

Rating for Qiagen NV (QGEN) Drops….. Weak Industry Group Rank

2017-11-09 investorplace
Qiagen NV (NASDAQ:QGEN) is one of 33 companies within the Life Sciences Tools & Services GICS industry group, which is in turn part of the 785 company GICS Health Care sector. QGEN has a market value of $7.7 billion which is in the top half of its industry group. The ranking for QGEN by Portfolio Grader places it 21 among the 33 companies in this industry group, giving it a lower than average position; in the top half of the sector with a ranking of 338 among the 785 companies in the sector, and number 2,179 in the nearly 5,000 company Portfolio Grader universe. (2-0)

HTGM / HTG Molecular Diagnostics, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2017-11-08 fintel.io
HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) has 23 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 3,694,329 shares. Largest shareholders include Qiagen Nv, Glaxosmithkline Plc, FMR LLC / Fidelity Management & Research, Cormorant Asset Management, LLC, and Vanguard Group Inc. (34-1)

QIAGEN NV (QGEN) Q3 2017 Results - Earnings Call Transcript

2017-11-07 seekingalpha
Ladies and gentlemen, thank you for standing by. Welcome, and thank you for joining QIAGEN's Conference to discuss the Third Quarter 2017 Results. At this time, all participants are in listen-only mode. Please be advised that this call is being recorded at QIAGEN's request and will be available on their website. The presentation will be followed by a question-and-answer session. (130-0)

QIAGEN (QGEN) Meets Q3 Earnings, Lags Revenues, Keeps View

2017-11-07 zacks
QIAGEN N.V. (QGEN - Free Report) reported third-quarter 2017 adjusted earnings per share of 32 cents, up 10.3% year over year. The reported figure is on par with the Zacks Consensus Estimate. (5-0)

Robust Quant Score Keeps Qiagen NV (QGEN) a Buy

2017-11-02 investorplace
Qiagen NV (NASDAQ:QGEN) is ranked as a Buy using the stock evaluator from Portfolio Grader, which incorporates Louis Navellier's investing methodology. QGEN has recently seen its Portfolio Grader rating upgraded from a Hold to a Buy. (2-0)

Can Molecular Diagnostics Drive Hologic's (HOLX) Q4 Earnings?

2017-11-01 zacks
Hologic, Inc. (HOLX - Free Report) is slated to report fourth-quarter fiscal 2017 financial results on Nov 8, after the closing bell. Last quarter, the company delivered a positive earnings surprise of 2%. Notably, Hologic’s earnings surpassed the Zacks Consensus Estimate in all of the past four quarters, the average beat being 4.2%. (10-0)

Healthy Earnings Momentum Keeps Qiagen NV (QGEN) a Buy

2017-10-26 investorplace
Portfolio Grader currently ranks Qiagen NV (NASDAQ:QGEN) a Buy. The methodology for investing incorporated in this analytical tool developed by Louis Navellier assesses and ranks nearly 5,000 stocks each week from a fundamental and quantitative perspective. QGEN has recently seen its Portfolio Grader rating upgraded from a Hold to a Buy. (2-0)

CUSIP: N72482107